In patients who present with a clinically isolated syndrome (CIS), whose features are suggestive of multiple sclerosis (MS), fulfilling McDonald 2010 magnetic resonance imaging (MRI) criteria for dissemination in space (DIS) and dissemination in time (DIT) enables a diagnosis of MS. While ⩾1 periventricular lesion is included in the 2010 DIS criteria, earlier McDonald criteria required ⩾3 periventricular lesions to confirm DIS and recent Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS)-recommended DIS criteria also require ⩾3 lesions. We investigated the effect of varying the required number of periventricular lesions and found that the best combination of specificity and sensitivity for clinically definite MS was seen for ⩾1 periventricular lesion using both the McDonald 2010 and MAGNIMS 2016 criteria.
Introduction
The McDonald criteria allow evidence on magnetic resonance imaging (MRI) for dissemination in space (DIS) and dissemination in time (DIT) to diagnose multiple sclerosis (MS) in patients with a clinically isolated syndrome (CIS). 1 MRI evidence for DIS in the McDonald 2010 criteria requires ⩾1 asymptomatic T2-hyperintense lesion in at least two of four regions typically affected by demyelination: periventricular (PV), juxtacortical, infratentorial and spinal cord. 1 The Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) group recently proposed new DIS criteria that include lesions in the optic nerve, cortex and symptomatic region, in addition to an increase in the required number of PV lesions from ⩾1 to ⩾3. 2 This latter recommendation was based on expert consensus and avoids a potential concern of a reduction in specificity should the symptomatic lesion and a single PV lesion alone constitute evidence for DIS.
A comparison of diagnostic criteria that differ only in the required number of PV lesions has not been previously undertaken. We therefore investigated the performance of ⩾1, ⩾2 and ⩾3 PV lesions in the 2010 McDonald criteria for the diagnosis of clinically definite multiple sclerosis (CDMS) in a prospective CIS cohort. The performance of the new MAGNIMS criteria 2 was also evaluated in a subgroup of patients in whom the symptomatic region had been imaged.
Methods
We studied 151 CIS patients (optic neuritis n = 124, brainstem syndrome n = 18, partial myelopathy n = 8 and hemispheric syndrome n = 1) from a prospectively recruited cohort. 3 Inclusion criteria were age 16-50 years, a typical CIS suggestive of MS and no previous history of neurological symptoms. The patients had T2-weighted and gadolinium-enhanced T1-weighted brain and spinal cord MRI within 3 months of symptom onset. Follow-up T2-weighted and gadolinium-enhanced T1-weighted brain MRI was done after 3 months. A single experienced neuroradiologist (K.A.M.) identified the number and location of T2-hyperintense and gadolinium-enhancing lesions. Patients were followed prospectively over approximately 15 years for the development of CDMS, requiring clinical evidence of a second episode and two separate lesions. 4 This study was approved by the Institutional Research Ethics Committee and all patients provided informed consent.
We retrospectively applied the McDonald 2010 DIS criteria that include ⩾1 PV lesion 1 and then applied the same DIS criteria with the single modification that either ⩾2 or ⩾3 PV lesions were required. 1 The McDonald 2010 DIT criteria 1 were also applied and both DIS plus DIT were required for a diagnosis of MS.
We similarly investigated varying the number of PV lesions for the proposed MAGNIMS 2016 criteria 2 in the subgroup of non-optic neuritis patients (n = 27) who had imaging of the symptomatic region, thus allowing inclusion of the symptomatic lesion when visible. 2 As optic nerve and double-inversion recovery images were not obtained, we could not investigate the effect of optic nerve or cortical lesions.
We tested performance of the DIS criteria using ⩾1, ⩾2 and ⩾3 PV lesions, alone and in combination with DIT, for the development of CDMS. We calculated the sensitivity, specificity and accuracy with 95% confidence interval (CI) as previously described. 5
Results
The demographic characteristics were typical of CIS patients (mean age: 32.4 years and 68% female). Over a mean follow-up period of 15.1 years (range: 11.0-19.7 years), 91 (60%) patients developed CDMS. The number of PV lesions at baseline and positive predictive value (PPV) for development of CDMS are shown in Table 1 .
Performance of the McDonald 2010 criteria using ⩾1, ⩾2 and ⩾3 PV lesions for development of CDMS is shown in Table 2 : ⩾1 PV lesion had a higher sensitivity and lower specificity than DIS criteria requiring ⩾2 or ⩾3 PV lesions. When DIS was combined with DIT, the sensitivity and accuracy of ⩾1 PV lesion was higher than ⩾2 or ⩾3 PV lesions and specificity was the same. Results were similar when applying the MAGNIMS 2016 criteria in the subgroup with imaging of the symptomatic region: ⩾1 PV lesion provided a higher sensitivity and the same specificity as ⩾2 or ⩾3 PV lesions ( Table 2) .
Discussion
Increasing the number of PV lesions required for DIS reduced the sensitivity of the 2010 McDonald MRI criteria for a diagnosis of CDMS possibly reflecting the lower lesion load at this earliest clinical stage of MS. Although a high sensitivity is desirable in contributing to more accurate diagnosis, a high specificity is more important, in order to minimise the risk of a false positive diagnosis. There was a decrease in specificity of DIS criteria requiring ⩾1 or ⩾2 PV lesions rather than ⩾3. However, when DIT criteria were added to DIS (as required to diagnose MS), the specificity of the 2010 McDonald criteria for CDMS was the same whether the minimum number of PV lesions was 1, 2 or 3.
The new MAGNIMS criteria include lesions in the symptomatic region in DIS (these are excluded in the McDonald 2010 criteria). 2 When we included such lesions in the small subgroup of non-optic neuritis CIS (n = 27), varying the number of PV lesions yielded similar findings to those reported for the whole cohort. A larger cohort should be studied to definitively investigate the effect of including symptomatic region lesions and varying the number of PV lesions. Additional cohort studies will also be needed to investigate the other new DIS imaging features recommended by MAGNIMS.
We studied a group of young adults with well-defined presentations typical of demyelination and a high pretest probability of MS. How MRI criteria perform outside this setting, for example, in people with atypical presentations or in older adults (>50 years) is uncertain and the likelihood of alternative diagnoses may be higher. Although synonymous with MS, PV lesions can occur in many disorders including migraine 6, 7 and small vessel cerebrovascular disease, 8 and a previous study found that ⩾3 PV lesions was the best MRI brain measure to differentiate MS from other neurological disorders. 8 Furthermore, T2-hyperintensities anterior to the frontal horns of the lateral ventricles ('PV capping') and the septum pellucidum are common findings on fluid-attenuated inversion recovery (FLAIR) sequences in healthy subjects and may be confused with MS lesions. 9 Because of the limited specificity of MRI lesion location per se, it remains absolutely essential that MRI criteria for MS are only applied in clinical settings where MS is strongly suspected, such as a young adult presenting with a typical CIS (e.g. unilateral optic neuritis and partial myelopathy) in order to avoid misdiagnosis. 1, 10 Even in typical CIS presentations, it is also important that the diagnostic contribution of PV lesions is not overemphasised or considered in isolation because (1) they are neither necessary nor sufficient for DIS (McDonald criteria require involvement of at least two of four clinically unaffected regions in CIS 1 ) and (2) DIT is required in addition to DIS in order to diagnose MS. The value of requiring DIT is also highlighted by the increase in specificity that we observed ( Table 2) . Within these caveats, our findings suggest that in young adult patients with a typical CIS, increasing the required number of PV lesions may not improve diagnostic accuracy. DIS only ⩾1 PV lesion 81% (72%-89%) 72% (59%-83%) 77% (70%-84%) 100% (75%-100%) 64% (35%-87%) 78% (62%-94%) ⩾2 PV lesions 74% (63%-82%) 75% (62%-85%) 74% (66%-81) 85% (55%-98%) 64% (35%-87%) 74% (54%-89%) ⩾3 PV lesions 70% (60%-79%) 77% (64%-87%) 73% (65%-80%) 77% (46%-95%) 64% (35%-87%) 70% (50%-86%) DIS + DIT combined ⩾1 PV lesion 64% (53%-74%) 78% (66%-88%) 70% (62%-77%) 92% (64%-100%) 71% (42%-92%) 81% (62%-94%) ⩾2 PV lesions 57% (46%-67%) 78% (66%-88%) 66% (57%-73%) 85% (55%-98%) 71% (42%-92%) 78% (58%-91%) ⩾3 PV lesions 55% (44%-65%) 78% (66%-88%) 64% (56%-72%) 77% (46%-95%) 71% (42%-92%) 74% (54%-89%) MS: multiple sclerosis; MAGNIMS: Magnetic Resonance Imaging in Multiple Sclerosis; MRI: magnetic resonance imaging; CI: confidence interval; DIS: dissemination in space; DIT: dissemination in time; PV: periventricular.
